119 related articles for article (PubMed ID: 10494754)
1. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Savage KJ; Wells PS; Schulz V; Goudie D; Morrow B; Cruickshank M; Kovacs MJ
Thromb Haemost; 1999 Sep; 82(3):1008-10. PubMed ID: 10494754
[TBL] [Abstract][Full Text] [Related]
2. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
4. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
5. Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience.
Heaton D; Han DY; Inder A
N Z Med J; 2002 Jul; 115(1158):U105. PubMed ID: 12362180
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
7. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Heidenreich C; Hohmann V; Bramlage P
Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
9. The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Niemi T; Silvasti-Lundell M; Armstrong E; Hernesniemi J
Acta Neurochir (Wien); 2009 Oct; 151(10):1289-94. PubMed ID: 19513580
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of upper-extremity deep venous thrombosis in a community teaching hospital.
Marinella MA; Kathula SK; Markert RJ
Heart Lung; 2000; 29(2):113-7. PubMed ID: 10739487
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
12. Home-treatment of deep vein thrombosis in patients with cancer.
Ageno W; Grimwood R; Limbiati S; Dentali F; Steidl L; Wells PS
Haematologica; 2005 Feb; 90(2):220-4. PubMed ID: 15710575
[TBL] [Abstract][Full Text] [Related]
13. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
[TBL] [Abstract][Full Text] [Related]
15. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M;
Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469
[TBL] [Abstract][Full Text] [Related]
17. Outpatient treatment of deep venous thrombosis: a clinical care pathway managed by the emergency department.
Vinson DR; Berman DA
Ann Emerg Med; 2001 Mar; 37(3):251-8. PubMed ID: 11223760
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.
Mismetti P; Mille D; Laporte S; Charlet V; Buchmüller-Cordier A; Jacquin JP; Fournel P; Dutrey-Dupagne C; Decousus H;
Haematologica; 2003 Jan; 88(1):67-73. PubMed ID: 12551829
[TBL] [Abstract][Full Text] [Related]
19. Upper extremity DVT in oncological patients: analysis of risk factors. Data from the RIETE registry.
Monreal M; Munoz FJ; Rosa V; Romero C; Roman P; Di Micco P; Prandoni P
Exp Oncol; 2006 Sep; 28(3):245-7. PubMed ID: 17080021
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).
Kovacs MJ; Kahn SR; Rodger M; Anderson DR; Andreou R; Mangel JE; Morrow B; Clement AM; Wells PS
J Thromb Haemost; 2007 Aug; 5(8):1650-3. PubMed ID: 17488349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
